Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines

Eijdems, E. W. H. M.; Haas, Marcel de; Timmerman, A. J.; Schans, G.P. van der; Kamst, Eric; Nooij, J. De; Ricotti, G.; Borst, Piet; Baas, Frank

doi:10.1038/bjc.1995.9

Cited by 29 publications

(16 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15) In contrast, decreased levels of Topo IIα gene expression are associated with resistance to Topo II inhibitors in lung cancer cell lines. [8][9][10] These results suggest that Topo IIα gene expression plays an important role in the action of Topo II inhibitors.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have demonstrated that decreased levels of Topo II gene expression are associated with resistance to Topo II inhibitors in some cancer cell lines. [8][9][10][11][12] Topo II inhibitors, such as etoposide, are widely used in lung cancer chemotherapy, but small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) show different sensitivity to them. 13,14) Previously we have demonstrated that sensitivity to etoposide, etoposide uptake, and the activity and content of Topo II are higher in SCLC cell lines than in NSCLC cell lines.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Differential Expression of DNA Topoisomerase IIα and IIβ Genes between Small Cell and Non‐small Cell Lung Cancer

Syahruddin

Oguri

Takahashi

et al. 1998

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Differential Expression of DNA Topoisomerase IIα and IIβ Genes between Small Cell and Non‐small Cell Lung Cancer

Syahruddin

Oguri

Takahashi

et al. 1998

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

“…In the case of doxorubicin selection, the supplementary resistance mechanism probably consists of alterations in topo Ila. Most of the MDR variants selected for doxorubicin resistance contained decreased topo Ilm mRNA levels, and the clones with normal mRNA level may nevertheless contain decreased topo II enzyme activity (Eijdems et al, 1995b …”

Section: Discussionmentioning

confidence: 99%

Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells

Eijdems

Zaman²,

Haas³

et al. 1995

Br J Cancer

Self Cite

View full text Add to dashboard Cite

“…Aberantna metilacija APC promotora 1A, RAR beta promotora P2, RASSF1A promotora povezana je sa gubitkom njegove genske ekspresije kod SCLC, ukazuju}i na fundamentalnu ulogu epigenetskih promena u patogenezi ove maligne bolesti. Implikacija ovih epigenetskih promena za dijagnozu i le~enje SCLC nije jo{ uvek odre|ena (72)(73)(74)(75)(76)(77).…”

Section: Markeri Metilacije Kod Tumora Plu}aunclassified

Recommendations For Clinical Use Of Tumor Markers In Lung Cancer

Stanković¹

2007

Journal of Medical Biochemistry

View full text Add to dashboard Cite

UvodKancer plu}a je najfrekventniji kancer u svetu kao i vode}i uzrok smrtnosti od kancera kod oba pola. Preivljavanje kod kancera plu}a zavisi uglavnom od tipa }elija i stadijuma bolesti u momentu otkrivanja bolesti prema TNM (tumor-node-metastasis) sistemu klasifikacije (tumor-node-metastasis). WHO histolo{ka klasifikacija kancera plu}a opisuje dva glavna entiteta koja zavise od tipa }elija: mikrocelularni kancer plu}a (SCLC) i nemikrocelularni kancer plu}a (NSCLC). SCLC je veoma agresivna bolest sa lo{om klini~kom prognozom i ~ini oko 15-25% svih kancera plu}a. Bez medicinskog tretmana, medijana du`ine pre`ivljavanja je od 1 do 3 meseca. Dobri rezultati se posti`u hemoterapijom i radioterapijom. NSCLC se sastoji iz 3 glavna histolo{ka tipa: karcinom skvamoznih }elija (SCC), adenokarcinom (AC) i gigantocelularni karcinom (LC), kojĩ ine ukupno 75% svih slu~ajeva kancera plu}a (1). Radikalna hirurgija sa kompletnom resekcijom tumora samo je osnova za le~enje pacijenata sa NSCLC i verovatno}a pre`ivljavanja uglavnom zavisi od stadijuma tumora. Uprkos kontinuiranom napretku u dijagnosti~kim metodama, kod 50-70% pacijenata s kancerom plu}a, bolest se dijagnostikuje u uznapredovalom stadijumu, isklju~ujuci na taj na~in mogu}nost radikalne terapije. Odre|ivanje tumorskih markera kod kancera plu}a mo`e biti od pomo}i u postavljanju dijagnoze, pra}enju pacijenta i terapije, a tako|e mo`e da pru`i dodatne informacije u prognosti~ke svrhe.Termin tumorski marker obuhvata ne samo one supstance koje se mogu meriti u krvi pacijenata (serumski markeri), ve} i abnormalne supstance identifikovane u tumorima plu}a ili njihovim metastazama, kao {to su molekularni markeri, markeri prognoze na- Kratak sadr`aj: Kancer plu}a predstavlja jedan od najozbiljnijih problema moderne onkologije. Uprkos kontinuiranom napretku u dijagnosti~kim metodama, kod 50-70% pacijenata s kancerom plu}a, bolest se dijagnostikuje u uznapredovalom stadijumu, isklju~ujuci na taj na~in mogu}nost radikalne terapije. Odre|ivanje tumorskih markera kod kancera plu}a mo`e biti od pomo}i u postavljanju dijagnoze, pra}enju pacijenta i terapije, a tako|e mo`e da pru`i dodatne informacije u prognosti~ke svrhe. U daljem tekstu opisani su odgovaraju}i serumski markeri kod dve glavne forme tumora plu}a-mikrocelularnog i nemikrocelularnog (SCLC i NSCLC), kao i abnormalne supstance identifikovane u tumorima plu}a ili njihovim metastazama, kao {to su molekularni markeri, markeri prognoze u primeni neoadjuvantne ili adjuvantne terapije i mikrometastazama ko{tane sr`i ili limfnom ~voru. Klju~ne re~i: tumorski markeri, kancer plu}a, mikrocelularni kancer plu}a, nemikrocelularni kancer plu}a Summary: Lung cancer presents one of the most serious problems of modern oncology. Despite the continual improvement and development of diagnostic methods, in 50-70% of lung cancer patients the disease is still diagnosed in advanced stages, excluding the possibility of radical therapy. The determination of tumor markers in lung cancer could be helpful in recognizing disease, follow-up, and...

show abstract

Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines

Abstract: Brsh J_suI d Caner (1.95) 71, [40][41][42][43][44][45][46][47] 00io © 1995 ocdktn Press Al rnghts rserved 0007-0920/95 $9.00 Reduced topoisomerase II

Cited by 29 publications

References 45 publications

Differential Expression of DNA Topoisomerase IIα and IIβ Genes between Small Cell and Non‐small Cell Lung Cancer

Differential Expression of DNA Topoisomerase IIα and IIβ Genes between Small Cell and Non‐small Cell Lung Cancer

Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells

Recommendations For Clinical Use Of Tumor Markers In Lung Cancer

Contact Info

Product

Resources

About